WO1998008514A1

WO1998008514A1 - Preventives/remedies for muscle tissue degenerations

Info

Publication number: WO1998008514A1
Application number: PCT/JP1997/002992
Authority: WO
Inventors: Norifumi Nakamura; Mamoru Koyama; Mizuo Miyazaki
Original assignee: Yoshitomi Pharmaceutical Industries, Ltd.; Asahi Glass Co., Ltd.
Priority date: 1996-08-30
Filing date: 1997-08-27
Publication date: 1998-03-05
Also published as: US6060480A; CN1235546A; CA2264101A1; EP0920866A4; KR20000035869A; EP0920866A1

Abstract

Preventives/remedies for muscle tissue degenerations containing as the active ingredient quinoline compounds represented by general formula (I) or pharmaceutically acceptable salts thereof. The preventives/remedies exert remarkable inhibitory and improving effects on muscle tissue degenerations such as necrosis, fibrosis or calcification. Thus, they are useful in the prevention and treatment of, in particular, cardiomyopathy, muscular dystrophy, pulmonary fibrosis, etc.

Description

Specification

Prevention and treatment of muscle tissue degeneration

Technical field

The present invention relates to a preventive / therapeutic agent for muscle tissue degeneration comprising a specific quinoline compound as an active ingredient.

Background art

In recent years, the number of patients with diseases associated with muscle tissue degeneration, such as cardiomyopathy, muscular dystrophy, and pulmonary fibrosis, has increased, and there has been significant interest in preventing and treating them.

Cardiomyopathy is an idiopathic cardiomyopathy and is classified into dilated (depressed blood) cardiomyopathy, hypertrophic cardiomyopathy, and restricted cardiomyopathy. Dilated cardiomyopathy is characterized by reduced ventricular dilatation and contractile function, degeneration of the left or both ventricular myocardium, atrophy and fibrosis of the interstitium, and manifests symptoms of depressive heart failure, with a severe prognosis. is there. In hypertrophic cardiomyopathy, the ventricle, mainly the ventricular septum, has unequal hypertrophy and irregular arrangement (complex arrangement) of myocardial cells. The prognosis varies from asymptomatic to heart failure, sudden death, and the like. Restrictive cardiomyopathy is mainly intractable due to diastolic dysfunction due to endocardial or subendocardial fibrous thickening, and is extremely refractory.

For cardiomyopathy, vasodilators (brazosin, hydralazine, etc.) and angiotensin converting enzyme inhibitors (captopril, etc.) are administered as symptomatic treatments for dilated cardiomyopathy. Although heart transplantation is an effective treatment, it is difficult in Japan. For hypertrophic cardiomyopathy; s blockers (such as probranolol) and Ca antagonists (such as verapamil and diltiazem) have been used.

However, all of the above treatments used in Japan are symptomatic treatments for each symptom of cardiomyopathy, not curative treatment by improving myocardial degeneration itself. In other words, conventional treatments cannot actively suppress the progression of the condition, and it is therefore difficult to reduce the risk of heart failure, sudden death, etc. associated with patients with cardiomyopathy o

No effective drug for muscular dystrophy or pulmonary fibrosis is the current situation.

On the other hand, in recent years, angiotensin II antagonists that are useful for treating hypertension and the like have been receiving attention. Angiotensin II antagonists have a strong vasoconstrictor effect and act on the adrenal cortex to stimulate secretion of aldosterone to increase blood pressure. It is a drug that has an antagonistic action in the body.

A report by Nakamura et al. (Am. J. Physiol. Dec. 1994, 267, H2297-2304) examined the effect of TCV-116, a typical angiotensin II antagonist, on hamsters with cardiomyopathy. However, although the drug was administered at high doses, its effects only showed an improvement in cardiac function and did not show a fundamental histological improvement effect. I have.

In view of the above circumstances, it has the effect of suppressing and improving the degeneration of muscle tissue such as necrosis, fibrosis, and calcification, which prevents cardiomyopathy, muscular dystrophy, pulmonary fibrosis, etc. The development of curable drugs is awaited.

Accordingly, an object of the present invention is to provide a preventive / therapeutic agent for muscle tissue degeneration capable of suppressing and improving necrosis, fibrosis, calcification and the like of muscle tissue.

Disclosure of the invention

The present inventors have conducted various studies to solve the above-mentioned problems and studied therapeutic methods for cardiomyopathy and the like.As a result, it has been known that the angiotensin II antagonist is useful for the treatment of hypertension and the like. For the first time, they have found that a specific quinoline compound or a pharmaceutically acceptable salt thereof has an excellent action of suppressing or improving degeneration such as necrosis, fibrosis, and calcification of muscle tissue, and completed the present invention.

That is, the present invention

(1) General formula (I):

[In the general formula (I), R '~R ⁸ shows the following.

R ¹ : lower alkyl group, halo lower alkyl group, cyclo lower alkyl group, alkenyl group, alkoxyl group, alkoxy lower alkyl group, or alkylthio group.

R ² , R ³ : both may be the same or different; each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a cyclo-lower alkyl group, an alkenyl group, an alkoxyl group, a _CraF; _{2m + i} —, one (CH ₂ ) n R ⁹ , or-(CH ₂ ) P COR '° o

R ⁴ : hydrogen atom, halogen atom, lower alkyl group, alkoxyl group, or C _m

F 2m + 1 "~ o

R ^5: a hydrogen atom, a halogen atom, One COOH, -COOR "s -CONH2, or one CN.

R ^6: over COOH, one C_〇_OR ^12, One CONH _2, one CN, -NH S 0 ₂ CF ₃ or C bond tetrazolyl group.

R ⁷ and R ^e : both may be the same or different, and each independently represents a hydrogen atom

, Halogen atom, lower alkyl group, alkoxyl group, or Cm F _{2 m +} i- ₀

X, Y: Both may be the same or different, and each is independently CH or a nitrogen atom. Here, R ^{9 to} R ′ ² , and m, n, and p indicate the following.

R ⁹ : hydroxy or alkoxyl group.

R ^1Q : a hydrogen atom, a hydroxyl group, a lower alkyl group, or an alkoxyl group. R ^l ', R ¹² : both may be the same or different, and each is independently a lower alkyl group, an alkenyl group, a cyclo lower alkyl group, an aryl group, or an alkyl group;

m is an integer from 1 to 6. n is an integer from 1 to 4. p is an integer from 0 to 4. ]

A preventive or therapeutic agent for muscle tissue degeneration comprising, as an active ingredient, a quinoline compound represented by or a pharmaceutically acceptable salt thereof,

(2) When the quinoline compound represented by the general formula (I) is N— {2- (6-) (2-ethyl-1,5,7-dimethyl-3H—imidazo [4,5-b] pyridine—3 —Yl) methyl] quinoline-1-yl} phenyl} trifluoromethanesulfonamide, the agent for preventing or treating muscle tissue degeneration according to (1),

(3) at least one selected from the group consisting of a prophylactic and therapeutic agent for cardiomyopathy, a prophylactic and therapeutic agent for muscular dystrophy, and a prophylactic and therapeutic agent for pulmonary fibrosis; the prevention of muscle tissue degeneration according to (1) or (2) Or therapeutic agent,

(4) a pharmaceutical composition for preventing or treating muscle tissue degeneration comprising a quinoline compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier,

(5) When the quinoline compound represented by the general formula (I) is N- {2-[&-[(2-ethyl-5,7-dimethyl-1 3 H-imidazo [4,5-b] pyridine-1 3 The pharmaceutical composition for preventing or treating muscle tissue degeneration according to (4), which is —yl) methyl] quinolin-1-2-yl} phenyl} trifluoromethanesulfonamide.

(6) The pharmaceutical composition for preventing or treating muscle tissue degeneration according to (4) or (5), wherein the muscle tissue degeneration is at least one selected from the group consisting of cardiomyopathy, muscular dystrophy and pulmonary fibrosis.

(7) An effective amount of a quinoline compound represented by the general formula (I) or a pharmaceutically acceptable compound thereof Preventing or treating muscle tissue degeneration comprising administering to the patient a salt that is

(8) —When the quinoline compound represented by the general formula (I) is N— {2- {6— [(2-ethyl-5,7-dimethyl-3H—imidazo [4,5-b] pyridine) 3-yl) methyl] quinoline-1-yl} phenyl} trifluoromethanesulfonamide, the method for preventing or treating muscle tissue degeneration according to (7),

(9) The method for preventing or treating muscle tissue degeneration according to (7) or (8), wherein the muscle tissue degeneration is at least one selected from the group consisting of cardiomyopathy, muscular dystrophy and pulmonary fibrosis.

(10) Use of a quinoline compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for preventing or treating muscle tissue degeneration,

(11) The quinoline compound represented by the general formula (I) is N- {2- (6-[(2-ethyl-1,5,7-dimethyl-1 3H-imidazo [4,5-b] pyridine) 3-yl) methyl] quinoline-1-yl} phenyl} trifluoromethanesulfonamide, the use according to (10),

(12) The use according to (10) or (11), wherein the muscle tissue degeneration is at least one selected from the group consisting of cardiomyopathy, muscular dystrophy and pulmonary fibrosis.

(13) The pharmaceutical composition for preventing or treating muscle tissue degeneration according to any of (4) to (6), and the pharmaceutical composition can be used or used for the prevention or treatment of muscle tissue degeneration A commercial package containing documentation that states

About.

The quinoline compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof used in the present invention is useful as an angiotensin II antagonist for the treatment of hypertension, etc., and has low toxicity and convenient absorption. It is a compound known to have properties such as stability, stability, and sustainability (Japanese Patent Application Laid-Open No. 6-80664).

—Pharmaceutically acceptable salts of the quinoline compounds represented by the general formula (I) include acid addition salts derived from the quinoline compounds and inorganic or organic acids. Such salts include, for example, hydrochloride, hydrobromide, sulfate, phosphate, methanesulfate Fonate, P-toluenesulfonate, oxalate, tartrate, citrate, maleate, fumarate, succinate, lactate, glutarate, acetate, trifluoroacetate There are various amino acid salts and the like.

The pharmaceutically acceptable salt of the quinoline compound represented by the general formula (I) includes a salt formed from the quinoline compound and a base. Such salts include, for example, those formed from alkali metals (eg, sodium and potassium), alkaline earth metals (eg, calcium, magnesium), ammonium and substituted ammonium (eg, dimethylammonium, triethylammonium) and the like. The salt that is to be removed.

In the above description and the following description of the present invention, “lower” organic group means 1 to 6 carbon atoms. The “lower alkyl group” may be linear or branched, and suitable examples thereof include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a t-butyl group, a pentyl group, Hexyl group and the like. “Halo lower alkyl group” is a lower alkyl group substituted with halogen, and suitable examples thereof include chloromethyl group, 2-chloroethyl group, bromomethyl group, 2-bromoethyl group, and 1,2- Examples include a dichloromethyl group, a 1,2-dibromoethyl group, and a 3-trifluoromethylpropyl group. "Lower cycloalkyl group" refers to a cycloalkyl group having 3 to 6 carbon atoms constituting a ring, and suitable examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, and a cyclohexyl group. No.

The alkenyl group is preferably a lower alkenyl group, more preferably a straight-chain or branched alkenyl group having 2 to 4 carbon atoms, and suitable examples thereof include a vinyl group, an aryl group and Examples thereof include a 1-propenyl group, an isopropenyl group, and a 1-butenyl group. The "alkoxyl group" is preferably a lower alkoxyl group, more preferably a linear or branched alkoxyl group having 1 to 4 carbon atoms, and suitable examples thereof include a methoxy group, an ethoxy group and a propoxy group. And butoxy groups. “Alkoxy lower alkyl group” includes It is preferable that the alkoxyl group is a lower alkoxyl group, and suitable examples thereof include a methoxethyl group, a 3-methoxypropyl group and a 2-ethoxyl group. As the “alkylthio group”, a lower alkylthio group is preferable, and suitable examples thereof include a methylthio group, an ethylthio group, a propylthio group, and a butylthio group.

Further, in the above description and the following description of the present invention, “halogen atom” means a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom. “Aryl group” refers to a monovalent aromatic hydrocarbon group, which may have a substituent (eg, a lower alkyl group, a halogen atom, a lower alkoxyl group, a lower alkylamino group, etc.) Preferred are a phenyl group and a derivative thereof. Examples thereof include a fuunyl group, a tolyl group, a p-halophenyl group (for example, a p-chlorophenyl group and a p-bromophenyl group), and an alkoxyphenyl group (for example, a methoxyphenyl group, An ethoxyphenyl group), a dialkylaminophenyl group (eg, a dimethylaminophenyl group, a getylaminophenyl group, and the like). Further, the “aralkyl group” refers to an aryl group-substituted alkyl group, and examples of the aryl group as a substituent include those described above. The alkyl group preferably has 1 to 4 carbon atoms. Suitable examples include benzyl, benzhydryl, trityl, phenethyl and the like.

Among the quinoline compounds represented by the general formula (I), R ¹ is preferably a lower alkyl group or an alkenyl group, and R ² and R ³ may be the same or different. Atom, halogen atom, lower alkyl group, — (CH ₂ ) „R ⁹ , or one (CH ₂ ) P COR ¹⁰ (where R ⁹ is a hydroxyl group or an alkoxyl group, R ¹ " is a hydrogen atom, a hydroxyl Group, or alkoxyl group, n is an integer of 1 to 4, p is an integer of 0 to 4), R ⁴ is a hydrogen atom, R ⁵ is a hydrogen atom, —COOH, or one COOR ″ (R ′ ¹ Is a lower alkyl group, an alkenyl group, a cyclo-lower alkyl group, an aryl group, or an aralkyl group; R ⁶ is —COOH, —COOR ¹² (R ′ 2 is a lower alkyl group, an alkenyl group, , —NHSO ₂ CF, or C-bonded tetrazolyl group, R ⁷ and R ⁸ may be the same or different, and each independently represents a hydrogen atom, a fluorine atom, A compound in which a chlorine atom, a lower alkyl group or an alkoxyl group, X is a nitrogen atom, and Y is CH.

More preferred among the quinoline compounds represented by the general formula (I) are those in which R ¹ is a lower alkyl group, R ² and R ³ may be the same or different, and each is independently a hydrogen atom A lower alkyl group, one (CH ₂ ) _n R ⁹ , or one (CH ₂ ) COR ¹⁰ (where R ⁹ is a hydroxyl group, R ′ is a hydrogen atom, a hydroxyl group or an alkoxyl group, n Is 1 and p is 0-1), R * is a hydrogen atom, R ⁵ is a hydrogen atom or a chlorine atom, R ⁶ is —COOH, —COOR ¹² (where R ¹² is a lower alkyl group, alkenyl group, a lower cycloalkyl group, Ariru group or aralkyl group), one NHS0 ₂ CF ₃ or C bond tetrazolyl group,, R ⁷ and R ⁸ may be the same or different, each independently represent a hydrogen atom, fluorine Element atom, chlorine atom or lower alkyl group, X is nitrogen atom Y is a compound is CH.

The most preferred quinoline compound in terms of the effect of preventing and treating muscle tissue degeneration is a compound represented by the following formula (II): N— {2- (6-) ((2-ethyl-5,7-dimethyl-3H) —Imidazo [4,5-b] pyridin-3-yl) methyl] quinoline-2-yl} phenyl} trifluoromethanesulfonamide and its pharmaceutically acceptable salts.

The quinoline compound represented by the general formula (I) used in the present invention is a known compound, and can be produced by a method known per se, for example, a method described in JP-A-6-80664. .

The agent for preventing and treating muscle tissue degeneration according to the present invention comprises, as an active ingredient, a quinoline compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, and comprises a human, a monkey, a dog, a cat, a dog, a dog. It has a marked inhibitory and ameliorating effect on degeneration such as necrosis, fibrosis, and calcification of muscle tissue of mammals such as cypress. In addition, compound (I) has low toxicity and excellent properties such as absorption, stability, and long-lasting properties. Therefore, it can be used advantageously for cardiomyopathy, muscular dystrophy, pulmonary line prevention and treatment. it can.

When the agent for preventing or treating muscle tissue degeneration according to the present invention is administered for treatment or prevention, the quinoline compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is used as an active ingredient, Tablets, granules, capsules, powders, etc., or liquid forms such as liquids, suspensions, syrups, emulsions, lemonade, etc. It is formulated into a dosage form suitable for administration or external use, and used as a pharmaceutical preparation. If necessary, supplements, stabilizing agents, wetting agents and other conventional additives such as lactose, citric acid, tartaric acid, stearic acid, magnesium stearate, terra alba, sucrose, corn starch, talc, Gelatin, agar, pectin, Peanut oil, olive oil, cocoa oil, ethylene glycol and the like may be added. An effective amount of the quinoline compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof is blended in the above preparation. The dosage depends on the route of administration, the type of disease, the condition of the patient, the weight or age, etc., but in general, a dose of 0.01 mg to about 50 Omg per day or more per patient is required. Good 0 The average dose is about 0.05 mg, 0.1 mg.0.25 mg.0.5 mg, 1 mg, 20 mg, 50 mg, 100 mg, 200 mg Alternatively, it may be used as 300 mg to prevent and treat muscle tissue degeneration.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is a diagram showing the total area of myocardium, the damaged area of tissue, and the area of calcification in control hamsters, cardiomyopathy hamsters to which a placebo drug was administered, and cardiomyopathy hamsters to which compound A was administered. Each value is the average soil standard error (η = 5-6). **: Ρ <0.01 (t-test for control group), +: Ρ <0.05, ++: P <0.01 (t-test for placebo drug administration group).

Example

Hereinafter, the present invention will be described more specifically with reference to Examples and Experimental Examples, but the present invention is not limited thereto.

[Reference Example] N- {2- [6-] [(2-ethyl-5,7-dimethyl-3H-imidazo [4,5-b] pyridin-3-yl) methyl] quinoline-1-yl } Production of trifluoromethanesulfonamide

2- {6-[(2-ethyl-5,7-dimethyl-13H-imidazo [4,5-b] pyridin-13-] produced by the method described in JP-A-6-80664. Le) Methyl] quinoline-l-yl} aniline (8.73 g, 21.4 mmo 1), triethylamine (6.Oml, 42.8 mmo 1), chloroform (87 ml) Mix, stir and cool in an ice bath while trifluoromethanesulfonic anhydride

A solution of (3.6 ml, 21.4 mmo 1) in black-mouthed form (36 ml) was added dropwise over 50 minutes. After stirring for 10 minutes, 2M acetic acid (123 ml) was added dropwise under ice cooling. Was. The layers were separated, and the organic layer was washed twice with ion-exchanged water (123 ml), once with 2% aqueous sodium bicarbonate (123 ml), and once with ion-exchanged water (123 ml). Crude N— {2-

{6-[(2-Ethyl-1,5,7-dimethyl-3H-imidazo [4,5-b] pyridin-1-3-yl) methyl] quinoline-1-2-yl) phenyl} Trifluoromethane sulfonami To give a solution of the form in the mouth. 60 ml of ethanol was added to this solution, and the solution was heated to a bath temperature of 90 to 115 ° C, and 1776 ml was distilled off. The mixture was allowed to stand at 0 ° C, and the precipitated crystals were collected by filtration. After washing three times with ethanol (1 O ml), the resultant was dried under reduced pressure. Take 8.36 g of 8.48 g of the obtained crystals, add ethyl acetate (425 m 1) and ethanol (175 m 1), heat, and evaporate 325 ml did. The mixture was allowed to stand at room temperature, and the precipitated crystals were collected by filtration. After washing with ethanol (10 ml) three times, the crystals were dried under reduced pressure to obtain 6.36 g of crystals. This recrystallization operation was performed again to obtain N- {2- {6-[(2-ethyl-5,71-dimethyl-3H-imidazo [4,5-b] pyridin-3-yl) methyl] quinoline-1 2- 5.52 g of yellow crystals of triphenylfluoromethanesulfonamide were obtained. Mp 2 52.0 ° C.

Ή-NMR (4 0 0 MH z, CDC 1 3) δ (p pm): 8. 2 2 (d, J = 9. 2 H z, 1 H); 7. 9 9 - 8. 0 5 (m 7.84 (d, J = 8.0 Hz, 1 H); 7.69 (dd, J = 8.6, 1.4 Hz, 1 H); 7.4 8 (t, J = 7.2 Hz, 1 H); 7.43 (s, 1 H); 7.29 (t, J = 8.0 Hz, 1 H); 6.94 (s, 1H); 5.67 (s, 2H); 2.82 (q, J = 7.6Hz, 2H); 2.67 (s, 3H); 2. 60 (s, 3H); 1.34 (t, J = 7.6Hz, 3H).

^{I 9 F-NMR (4 0} 0 MH z, CD C 1 3) δ (p pm): - 7 7. 1 8

Three

(Experimental example)

Cardiomyopathy inhibitory effect test

Cardiomyopathic hamsters (Bi 0 14.6: male, 4 weeks old) were divided into two groups, and one group (6 specimens) was treated with N- {2-{6-((2-ethyl--5,7-dimethyl). One 3 H—Imidazo [ 4, 5-b] pyridine-1-3-yl) methyl] quinoline-12-yl} phenyl} trifluoromethanesulfonamide (hereinafter abbreviated as compound A) (SmgZkg) and other groups ( (5 specimens) were orally administered a placebo drug (3 mg / kg) once a day for 9 weeks. Bi0F1B (male, 4 weeks old) was bred as a control hamster under the same conditions as above for 9 weeks (5 samples). After 9 weeks, the following evaluation was performed.

1. Evaluation by histological analysis of the heart

(Sample preparation method)

After sacrifice of the animals, the heart was removed and fixed in 10% neutral buffered formalin. The heart was divided into 5 parts, each slice was paraffin-embedded with the same side facing up, and four myocardial pathological specimens were prepared per specimen.

Azan staining of the above specimens [edited by The Pathological Society of Japan: Pathology Technical Manual 3. Pathological tissue preparation method (2) Staining method. 46-51, Dentistry Publishing, 1981] and Ca staining [Japanese pathology Society: Pathology Technical Manual 3. Pathological Tissue Specimen Preparation Technology (Lower) Staining Method. 143-147, Dentistry Publishing, 1981] and image analysis of total myocardial area, tissue lesion area and calcification area The measurement was performed using an instrument [LUZEX-F, manufactured by NI RECO Corporation].

(Evaluation method 1)

The damaged area and the calcified area of the tissue were evaluated by the average area of all the specimens (the former: 24 specimens and the latter: 20 specimens) of the compound A administration group and the placebo drug administration group. The results are shown in Tables 1 and 2.

Table 1 Tissue damage area (mm ² ) Compound A administration group (n = 24) 0.58 ± 0.1

Placebo group (n = 20) 1.22 ± 0.2 p <0.01 Table 2

Tissue calcification area (mm ² ) Compound A administration group (n = 24) 0.19 ± 0.01

Placebo group (n = 20) 0.45 ± 0.09

P <0.01

(Evaluation method 2)

The sum of the areas of the four specimens obtained from each specimen is defined as the area of the specimen, and the area of all the specimens in the compound A administration group, placebo drug administration group, and control group for the myocardial area, tissue lesion area, and tissue calcification area The average value was evaluated. The results are shown in Figure 1. [Result]

The heart of cardiomyopathy hamsters (placebo-treated group) showed remarkable myocardial atrophy, and cardiac muscle necrosis, fibrosis, and calcification were observed. In the compound A-administered group, myocardial atrophy and the area of the affected area Was significantly suppressed. Compound A administration was found to markedly improve the pathological histopathology of the heart of cardiomyopathic hamsters.

2. Other evaluations

Serum biochemical analysis showed that serum LDH, GOT, GPT, and CPK levels were significantly increased in cardiomyopathy hamsters, but Compound 投与 administration significantly suppressed these increases. In addition, administration of Compound A did not significantly change body weight, cardiac weight, or blood pressure.

The following shows formulation examples.

Formulation example 1

Tablets

1) Compound A 1 0.0 mg

2) Fine particles for direct hit No. 2 09 (Fuji Chemical Co., Ltd.) 46.6 mg Sodium aluminate metasilicate 20 wt% Corn starch 30 wt% Lactose 50 wt%

3) Microcrystalline cellulose 24.0 mg

4) Carboxymethylcellulose-calcium 4.0 mg

5) 0.4 mg of magnesium stearate 1), 3) and 4) are all passed through a 100 mesh sieve in advance. This 1)

, 3), 4) and 2) are each dried to reduce the water content to a certain level, and then mixed with the above weight ratio using a mixer. Add 5) to the mixed powder of uniform quality, mix for a short time (30 seconds), tablet the mixed powder (punch: 6.3 mm0, 6.0 mmR), and 8.5 mg per tablet Tablets.

If necessary, the tablet may be coated with a commonly used gastrosoluble film coating agent (for example, polyvinylacetate-l-jetylaminoacetate) or an edible colorant.

Formulation example 2

Capsule

1) Compound A 50 g

2) Lactose 9 3 5 g

3) 15 g of magnesium stearate Each of the above components was weighed and mixed uniformly, and the mixed powder was filled into a hard gelatin capsule at 20 mg each.

Formulation example 3

Injection

1) Compound A 5 mg

2) Saccharose 100 mg

3) 10 ml of physiological saline The above mixture was filtered through a membrane filter, sterilized and filtered again, and the filtrate was aseptically dispensed into vials, filled with nitrogen gas, and sealed. Intravenous injection Agent.

Industrial applicability

The agent for preventing and treating muscle tissue degeneration according to the present invention has an excellent ameliorating effect on tissue lesions such as necrosis, fibrosis, and calcification of muscle tissue, and has low toxicity. It is useful for the prevention and treatment of muscular dystrophy, pulmonary fibrosis, etc. This application is based on Japanese Patent Application No. 2300936 filed in Japan, the contents of which are incorporated in full herein.

Claims

The scope of the claims

1. General formula (I)

[In the general formula (I), R '~R ⁸ shows the following.

R ² , R ³ : both may be the same or different; each independently represents a hydrogen atom

, Halogen atom, lower alkyl group, halo lower alkyl group, cyclo lower alkyl group

, An alkenyl group, an alkoxyl _{_{group, C M F 2M + 1 -}} , - (CH 2) "R 9 or a, (CK J___P COR '° o

R ⁴ : hydrogen atom, halogen atom, lower alkyl group, alkoxyl group, or _CRA

F 2m + l.

R ⁵ : hydrogen atom, halogen atom, one COOH, -COOR ", -CONH ₂ , or one CN.

R ⁶ : —COOH, one COOR ¹² , one CONH ₂ , one CN, —NHSO ₂ CF ₃ or a C-bonded tetrazolyl group.

R ^7, R ^8: both may be the same or different, each independently, a hydrogen atom, a halogen atom, a lower alkyl group, an alkoxyl group or a _{_{C M F 2M + 1, -}} . X, Y: Both may be the same or different, and each is independently CH or a nitrogen atom.

Here, the above R ^{9 to} R ¹² , and m, n, and p indicate the following.

R ^g : hydroxy or alkoxyl group.

R '. : Hydrogen atom, hydroxyl group, lower alkyl group, or alkoxyl group. R ^ll and R ¹² : both may be the same or different and each independently represents a lower alkyl group, an alkenyl group, a cyclo-lower alkyl group, an aryl group or an alkyl group;

A preventive or therapeutic agent for muscle tissue degeneration comprising, as an active ingredient, a quinoline compound represented by the formula: or a pharmaceutically acceptable salt thereof.

2. When the quinoline compound represented by the general formula (I) is N- {2- (6-[(2-ethyl-5,7-dimethyl-13H-imidazo [4,5-b] pyridine-13-) 2. The agent for preventing or treating muscle tissue degeneration according to claim 1, wherein the agent is methyl) quinoline-1-yl} phenyl} trifluoromethanesulfonamide.

3. The muscle tissue according to claim 1 or 2, which is at least one selected from the group consisting of a cardiomyopathy prevention and treatment agent, muscular dystrophy prevention and treatment agent, and pulmonary fibrosis prevention and treatment agent. Agent for preventing or treating degeneration.

4. General formula (I):

[In the general formula (I), R '~R ⁸ shows the following.

R ¹ : lower alkyl group, halo lower alkyl group, cyclo lower alkyl group, alkenyl group, alkoxyl group, alkoxy lower alkyl group, or alkylthio group. R ² and R ³ : both may be the same or different, and each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a cyclo-lower alkyl group, an alkenyl group, an alkoxyl group, C _m F _{2m + 1} —, one (CH ₂ ) R ⁹ , or one (CH ₂ ) P COR ^{l 0} o

R ⁴ : hydrogen atom, halogen atom, lower alkyl group, alkoxyl group, or C _m

F 2m + 1 ^— o

R ⁵ : hydrogen atom, halogen atom, —COOH, —COOR ^u , one CONH ₂ , or one CN.

R ⁶ : —COOH, —COOR ¹² , one CONH ₂ , one CN, one NHSO ₂ CF ₃ or C-bonded tetrazolyl group.

R ⁷ and R ⁸ : They may be the same or different, and each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, an alkoxyl group, or C _m F _{2m + 1} —. X, Y: Both may be the same or different, and each is independently CH or a nitrogen atom. Here, the above R ^{9 to} R ¹² , and m, n, and p indicate the following.

R ⁹ : hydroxy or alkoxyl group.

Hydrogen atom, hydroxyl group, lower alkyl group, or alkoxyl group. R ¹² : Both may be the same or different, and each independently represents a lower alkyl group, an alkenyl group, a cyclo-lower alkyl group, an aryl group, or an alkyl group.

A pharmaceutical composition for preventing or treating muscle tissue degeneration, comprising a quinoline compound represented by the formula or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

5. —The quinoline compound represented by the general formula (I) is N— {2— {6 — [(2-Ethyl-1,5,7—dimethyl-13H—imidazo [4,5—b] pyridine-13— 5. The pharmaceutical composition for preventing or treating muscle tissue degeneration according to claim 4, which is [yl] methyl] quinoline-1-yl} phenyl} trifluoromethanesulfonamide.

6. The pharmaceutical composition for preventing or treating muscle tissue degeneration according to claim 4 or 5, wherein the muscle tissue degeneration is at least one selected from the group consisting of cardiomyopathy, muscular dystrophy and pulmonary fibrosis.

7. General formula of effective amount (I):

[In the general formula (I), R ^{1 to} R ⁸ represent the following.

R ² , R ³ : both may be the same or different; each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a cyclo-lower alkyl group, an alkenyl group, an alkoxyl group, a _CraF; _{2m + 1} ―, one (CH ₂ ) _n R ⁹ , or-(CH ₂ ) P COR ^{10 0} o

R ⁴ : hydrogen atom, halogen atom, lower alkyl group, alkoxyl group, or Cm

I "2 m + 1 ^— o

R ⁵ : hydrogen atom, halogen atom, COOH, -COOR ". -CONH2, or CN.

R ^6: over COOH, one COOR ^'2, -CONH2, one CN, -NHS O _z CF ₃ or C bond tetrazolyl group.

R ⁷ , R ⁸ : both may be the same or different, each independently being a hydrogen atom

, A halogen atom, a lower alkyl group, an alkoxyl group, or Cm F _{2m + l} .

X, Y: Both may be the same or different, and each is independently CH or a nitrogen atom.

Here, the above R ^{9 to} R ¹² , and m, n, and p indicate the following.

R ⁹ : a hydroxyl group or an alkoxyl group.

R '°: hydrogen atom, hydroxyl group, lower alkyl group, or alkoxyl group.

R ^ll and R ¹² : both may be the same or different and each independently represents a lower alkyl group, an alkenyl group, a cyclo-lower alkyl group, an aryl group or an alkyl group;

A method for preventing or treating muscle tissue degeneration comprising administering to a patient a quinoline compound represented by the formula: or a pharmaceutically acceptable salt thereof.

8. —When the quinoline compound represented by the general formula (I) is N— {2- -6-((2-ethyl) -5,7-dimethyl-13-imidazo [4,5-b] pyridine-13-yl) methyl] quinoline-12-yl} phenyl} trifluoromethanesulfonamide Claim 7 The method for preventing or treating muscle tissue degeneration according to the above item.

9. The method for preventing or treating muscle tissue degeneration according to claim 7, wherein the muscle tissue degeneration is at least one selected from the group consisting of cardiomyopathy, muscular dystrophy and pulmonary fibrosis.

10. General formula (I) for the manufacture of a medicament for preventing or treating muscle tissue degeneration:

[In the general formula (I), R '~R ⁸ shows the following.

R ': lower alkyl group, halo lower alkyl group, cyclo lower alkyl group, alkenyl group, alkoxyl group, alkoxy lower alkyl group, or alkylthio group. R ² and R ³ : both may be the same or different, and each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, a halo-lower alkyl group, a cyclo-lower alkyl group, an alkenyl group, an alkoxyl group, C _m F _{2m + I} ―, one (CH ₂ ) _n R ⁹ , or one (CH ₂ ) P COR ^{10 0} o

R ⁴ : hydrogen atom, halogen atom, lower alkyl group, alkoxyl group, or C „

F 2m one o

R ⁵ : hydrogen atom, halogen atom, —COOH, —COOR'-C〇NH ₂ , or Or one CN.

R ^6: - COOH, one COOR ^'2, -CONHa, one CN, -NHS0 ₂ CF ₃ or C bond tetrazolyl group.

R ⁷ and R ⁸ : both may be the same or different, and each independently represents a hydrogen atom, a halogen atom, a lower alkyl group, an alkoxyl group, or C _m F _{2m +1} —. X, Y: Both may be the same or different, and each is independently CH or a nitrogen atom.

Here, R ^{9 to} R ′ ² , and m, n, and p indicate the following.

R ⁹ : hydroxy or alkoxyl group.

R '°: hydrogen atom, hydroxyl group, lower alkyl group, or alkoxyl group. R ′ ¹ R ¹² : Both may be the same or different and are each independently a lower alkyl group, an alkenyl group, a cyclo-lower alkyl group, an aryl group, or an alkyl group.

Or a pharmaceutically acceptable salt thereof.

1 1. When the quinoline compound represented by the general formula (I) is N— {2— {6 — [(2-ethyl-5,7—dimethyl-13H—imidazo [4,5—b] pyridine-13 —Yl) methyl] quinoline-1-yl) phenyl} trifluoromethanesulfonamide.

12. The use according to claim 10 or 11, wherein the muscle tissue degeneration is at least one selected from the group consisting of cardiomyopathy, muscular dystrophy and pulmonary fibrosis.

1 3. A pharmaceutical composition for preventing or treating muscle tissue degeneration according to any one of claims 4 to 6, and the pharmaceutical composition can be used for preventing or treating muscle tissue degeneration. Commercial package containing documentation stating that it should be used.